Daiichi Sankyo Company, Limited (DSKYF) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Tokyo, Japan. The current CEO is Hiroyuki Okuzawa.
DSKYF has IPO date of 2008-06-24, 18,726 full-time employees, listed on the Other OTC, a market capitalization of $32.23B.
Daiichi Sankyo Company, Limited is a Tokyo-based pharmaceutical company founded in 1899 that researches, develops, manufactures, and markets a diverse portfolio of prescription and over-the-counter medicines globally. The company's core therapeutic areas include oncology, cardiovascular disease, diabetes, pain management, and infectious disease, with key products such as Enhertu (trastuzumab deruxtecan) for cancer treatment, edoxaban for anticoagulation, and teneligliptin for diabetes management. Beyond pharmaceuticals, Daiichi Sankyo operates across consumer health, vaccines, animal health, cosmetics, and medical devices. The company has established strategic collaborations, including a partnership with Guardant Health to develop companion diagnostics, and maintains a strong commitment to innovation across multiple healthcare segments.
